BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 25683509)

  • 21. The protease-sensitive N-terminal polybasic region of prion protein modulates its conversion to the pathogenic prion conformer.
    Zhang X; Pan YH; Chen Y; Pan C; Ma J; Yuan C; Yu G; Ma J
    J Biol Chem; 2021 Nov; 297(5):101344. PubMed ID: 34710372
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The paraffin-embedded tissue blot detects PrP(Sc) early in the incubation time in prion diseases.
    Schulz-Schaeffer WJ; Tschöke S; Kranefuss N; Dröse W; Hause-Reitner D; Giese A; Groschup MH; Kretzschmar HA
    Am J Pathol; 2000 Jan; 156(1):51-6. PubMed ID: 10623653
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preventing misfolding of the prion protein by trimethylamine N-oxide.
    Bennion BJ; DeMarco ML; Daggett V
    Biochemistry; 2004 Oct; 43(41):12955-63. PubMed ID: 15476389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protein misfolding cyclic amplification of prions.
    Saunders SE; Bartz JC; Shikiya RA
    J Vis Exp; 2012 Nov; (69):. PubMed ID: 23168797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glypican-1 mediates both prion protein lipid raft association and disease isoform formation.
    Taylor DR; Whitehouse IJ; Hooper NM
    PLoS Pathog; 2009 Nov; 5(11):e1000666. PubMed ID: 19936054
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prion proteins: a biological role beyond prion diseases.
    Hu W; Rosenberg RN; Stüve O
    Acta Neurol Scand; 2007 Aug; 116(2):75-82. PubMed ID: 17661791
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-prion drug mPPIg5 inhibits PrP(C) conversion to PrP(Sc).
    McCarthy JM; Franke M; Resenberger UK; Waldron S; Simpson JC; Tatzelt J; Appelhans D; Rogers MS
    PLoS One; 2013; 8(1):e55282. PubMed ID: 23383136
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Towards cellular receptors for prions.
    Lee KS; Linden R; Prado MA; Brentani RR; Martins VR
    Rev Med Virol; 2003; 13(6):399-408. PubMed ID: 14625887
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential solubility of prions is associated in manifold phenotypes.
    Kuczius T; Karch H; Groschup MH
    Mol Cell Neurosci; 2009 Nov; 42(3):226-33. PubMed ID: 19607920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heterogeneity and Architecture of Pathological Prion Protein Assemblies: Time to Revisit the Molecular Basis of the Prion Replication Process?
    Igel-Egalon A; Bohl J; Moudjou M; Herzog L; Reine F; Rezaei H; Béringue V
    Viruses; 2019 May; 11(5):. PubMed ID: 31083283
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human prion diseases: from Kuru to variant Creutzfeldt-Jakob disease.
    Sikorska B; Liberski PP
    Subcell Biochem; 2012; 65():457-96. PubMed ID: 23225013
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The retention of prion protein in the endoplasmic reticulum prevents N2A cells from proteasome inhibition-induced cytotoxicity.
    Fang S; Wang R; Liu H; Zhuang W; Wang Z; Zhang J; Pei L; Liu Y; Su Y
    Biochem Biophys Res Commun; 2017 Sep; 491(2):500-507. PubMed ID: 28669732
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Charged bipolar suramin derivatives induce aggregation of the prion protein at the cell surface and inhibit PrPSc replication.
    Nunziante M; Kehler C; Maas E; Kassack MU; Groschup M; Schätzl HM
    J Cell Sci; 2005 Nov; 118(Pt 21):4959-73. PubMed ID: 16219680
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Misfolding of the prion protein at the plasma membrane induces endocytosis, intracellular retention and degradation.
    Kiachopoulos S; Heske J; Tatzelt J; Winklhofer KF
    Traffic; 2004 Jun; 5(6):426-36. PubMed ID: 15117317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The molecular biology of prion propagation.
    Clarke AR; Jackson GS; Collinge J
    Philos Trans R Soc Lond B Biol Sci; 2001 Feb; 356(1406):185-95. PubMed ID: 11260799
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Calpain-dependent endoproteolytic cleavage of PrPSc modulates scrapie prion propagation.
    Yadavalli R; Guttmann RP; Seward T; Centers AP; Williamson RA; Telling GC
    J Biol Chem; 2004 May; 279(21):21948-56. PubMed ID: 15026410
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PrP(Sc) of scrapie 263K propagates efficiently in spleen and muscle tissues with protein misfolding cyclic amplification.
    Shi S; Dong CF; Wang GR; Wang X; An R; Chen JM; Shan B; Zhang BY; Xu K; Shi Q; Tian C; Gao C; Han J; Dong XP
    Virus Res; 2009 Apr; 141(1):26-33. PubMed ID: 19162101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allelic Interference in Prion Replication Is Modulated by the Convertibility of the Interfering PrP
    Espinosa JC; Andreoletti O; Marín-Moreno A; Lugan S; Aguilar-Calvo P; Cassard H; Lorenzo P; Douet JY; Villa-Díaz A; Aron N; Prieto I; Huor A; Torres JM
    mBio; 2021 Mar; 12(2):. PubMed ID: 33727358
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficient in vitro amplification of a mouse-adapted scrapie prion protein.
    Murayama Y; Yoshioka M; Yokoyama T; Iwamaru Y; Imamura M; Masujin K; Yoshiba S; Mohri S
    Neurosci Lett; 2007 Feb; 413(3):270-3. PubMed ID: 17174030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monoacylated cellular prion protein modifies cell membranes, inhibits cell signaling, and reduces prion formation.
    Bate C; Williams A
    J Biol Chem; 2011 Mar; 286(11):8752-8. PubMed ID: 21212283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.